PCSK9 and metabolic syndrome: The primary objective of the PERI-DYS study was to compare the target goal attainment in LDL-C values and general differences in patient characteristics in two cohorts of dyslipidemia patients at very high CV risk: those receiving PCSK9-mAb and those eligible but not receiving these inhibitors.